The fenben for cancer drug is a molecule that inhibits glucose uptake in cancer cells. It works by stabilizing the p53 gene, interfering with glucose metabolism, and inhibiting the growth of cancer cells. These effects may make it advantageous in avoiding drug resistance. fenben is also less expensive than its human equivalent, Albendazole. Albendazole can cost $115 to $185 per tablet, even with a coupon.
Benzimidazole compounds have long been known to interfere with the energy metabolism of a host cell. They block glucose uptake and ATP production in the host cell, leading to the death of the parasite. It has been noted for some time that malignant cell lines have higher glucose consumption than normal cells. This discrepancy has been exploited therapeutically. In studies, FZ inhibited glucose uptake in NSCLC cells and induced their death.
DNTC formulations of fenbendazole have been tested in mice. The combination of DNTC with fenbendazole improves bioavailability and systemic absorption of the drug. It also induces apoptosis in tumor cells and lowers ED50.
This tapeworm drug may prove to be an effective cancer treatment. It could help reduce the cost and time required to develop candidate therapeutics. It can also speed up the pipeline for available therapeutics. But it has a significant risk associated with it. This means it needs to be evaluated carefully before being used.
AT6.1 prostate cancer cells were used to create a model for cancer cells. These cells were injected into a nude mouse five days prior to treatment. Throughout the course of treatment, the drugs were administered intraperitoneally three times a week. Until signs of morbidity were observed, the drug was given to the mice intraperitoneally. The drugs were diluted in DMSO and saline. Survival rates were assessed using Kaplan-Meier survival curves.